SAGA Diagnostics names new CEO
8 October 2021 -

SAGA Diagnostics AB, a Sweden-based cancer liquid biopsy and genomic testing company, announced on Thursday that it has named Peter Collins as its new chief executive officer.

Collins is a highly experienced entrepreneur with more than 30 years of experience in the pharma and diagnostics sector. He has served as chief business officer at Inivata, VP Biopharma Business Development at Guardant Health, CBO of Yourgene, and VP, head of Diagnostics at GSK.

Collins said, 'SAGA is an outstanding company with a leading technology and solid market traction. Ultrasensitivity and detection of minimal residual disease (MRD) is exactly what biopharma, the clinical testing market and cancer patients need. SAGA has a diverse and exceptionally talented team already in place – I'm excited to lead this next phase of growth, build out the team further, and execute on a strategy to rapidly bring our technologies into the clinics to benefit more people living with cancer.'